TY  - JOUR
AU  - Grávalos, C
AU  - Sanmartín, O
AU  - Gúrpide, A
AU  - España, A
AU  - Majem, M
AU  - Suh Oh, H J
AU  - Aragón, I
AU  - Segura, S
AU  - Beato, C
AU  - Botella, R
PY  - 2018
DO  - 10.1007/s12094-018-1953-x
UR  - http://hdl.handle.net/10668/13022
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However,...
LA  - en
KW  - Anti-EGFR
KW  - Antiangiogenic drugs
KW  - Dermatological toxicity
KW  - Immune checkpoint inhibitors
KW  - MTOR inhibitors
KW  - Targeted therapies
KW  - Antineoplastic Agents
KW  - Consensus
KW  - Dermatology
KW  - Disease Management
KW  - Humans
KW  - Immunotherapy
KW  - Molecular Targeted Therapy
KW  - Neoplasms
KW  - Quality of Life
KW  - Skin Diseases
KW  - Societies, Medical
KW  - Venereology
TI  - Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
TY  - research article
VL  - 21
ER  -